Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

Authors

Masaki Ishida, Tadaaki Yamada, Ou Yamaguchi, Yasuhiro Goto, Tomohiro Oba, Kazuki Shimamoto, Takeshi Tsuda, Ichidai Tanaka, Shizuka Shiraishi, Naoki Furuya, Akihiro Yoshimura, Keisuke Mine, Tomoaki Ota, Makoto Hibino, Yoshihito Kogure, Toshiyuki Iwata, Satoshi Watanabe, Hisashi Tanaka, Tamio Okimoto, Izumi Sato, Misaki Sasakura, Koki Nakashima, Yutaka Morita, Shunsuke Misono, Naoko Ishizaki, Keiko Tanimura, Hayato Kawachi, Naoya Nishioka, Masahiro Iwasaku, Koichi Takayama

Published in

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. Pages 106103. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

First-line osimertinib monotherapy remains a standard treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), although intensified regimens improve outcomes at the cost of an increased toxicity and treatment burden. We characterized pretreatment clinical features associated with a long-term benefit (LTB) and developed an exploratory clinical score.
This retrospective cohort comprised patients receiving first-line osimertinib monotherapy for advanced or recurrent EGFR-mutated NSCLC at 25 Japanese institutions between September 2018 and March 2022. An LTB was defined as both progression-free survival (PFS) ≥24 months and overall survival (OS) ≥48 months, based on the FLAURA2 trial. Factors associated with an LTB were evaluated using multivariable logistic regression. Six independently associated favorable factors were each assigned a score of 1 if present, yielding an exploratory 0-6-point score.
Among 803 included patients, 204 (25.4%) experienced an LTB. The six independently associated factors were age <75 years, an Eastern Cooperative Oncology Group performance status of 0-1, a serum albumin level ≥3.5 g/dL, postoperative recurrence, EGFR exon 19 deletion, and the absence of liver metastasis. LTB rates were 2.5%, 19.0%, and 50.7% in the 0-2-, 3-4-, and 5-6-point groups, respectively (P for trend<0.001). The median PFS was 7.2, 16.8, and 30.5 months, and the median OS was 12.7, 35.9, and 68.3 months, respectively.
This exploratory score may support prognostic stratification regarding the likelihood of durable outcomes with osimertinib monotherapy but does not establish whether monotherapy should be preferred over an intensified regimen.

PMID:
42767607
Bibliographic data and abstract were imported from PubMed on 22 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.